By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Great Emphasis is Put on Research.

AFFiRiS AG

The Viennese biotech company is playing a decisive role in the development of vaccines. With their team of almost 100 specialists, the founders Walter Schmidt and Frank Mattner are developing vaccines against previously untreatable or hardly treatable diseases such as Alzheimer’s, atherosclerosis and Parkinson’s.

www.affiris.at

 

Please find more information on Research & Development in Austria here.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Austria and Catalonia: international Trade & Investment locations facing successfully post-COVID-19 future

    21.07.2020, 15:30-17:30, Online Conference

  • BIOMEDevice Boston 2020

    16. - 17.09.2020, Boston, USA

Austria Map

Find the perfect location for your company

One of Austria's key strengths as a business destination is its highly qualified and motivated skilled workforce for research and development, especially in the scientific sector.

Nestlé Austria

Logo
More testimonials

news from the business location Austria

Top Score for Lockdown – Austria convinces in current Deloitte entrepreneur survey with well thought out Covid-19 measures

Austria convinces in current Deloitte survey and gets top score for well thought out Covid-19 measures.

Concerning Facebook and LinkedIn: Austrian companies in the social media jungle

A growing number of companies are relying on social media to inform customers, open up new target groups and identify suitable employees. Firms are increasingly investing in Facebook and other social media as each year passes, However, at the same time the continuous further development and establishment of networks are also leading to uncertainties about the right way of handling these platforms.

More news All blog posts